Joe Palca
Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics 鈥� everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers 鈥� A science communication collective.
Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.
In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.
Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.
With Flora Lichtman, Palca is the co-author of (Wiley, 2011).
He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.
-
The Food and Drug Administration has released detailed information about the Pfizer/BioNTech Covid-19 vaccine. The material will be evaluated later this week by an independent committee of experts.
-
The White House coronavirus task force briefed reporters on Thursday for the first time in months as the Centers for Disease Control and Prevention warned Americans to avoid travel.
-
The vaccine was found to be 95% effective in an updated study analysis. Safety data required by the Food and Drug Administration showed no serious concerns, the company said. -
The vaccine is nearly 95% effective in preventing illness, according to an interim analysis of a clinical test involving 30,000 people. -
Pfizer and partner BioNTech say that their COVID-19 vaccine was 90% effective in a group of 94 volunteers. The companies say it could be submitted for FDA approval this month or next.
-
Pfizer's COVID-19 vaccine is the first to have data showing that it exceeded the minimum effectiveness threshold set by the Food and Drug Administration for emergency use. -
The British government has announced plans for a coronavirus vaccine challenge trial. Volunteers will receive an experimental vaccine and be exposed to the virus to test its efficacy.
-
Here's irony: tobacco plants may be key in preventing COVID-19. Two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is already in a clinical trial. -
Historically tobacco plants are responsible for their share of illness and death. But two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is in clinical trials.
-
The president's doctor has offered a fairly upbeat assessment of Trump's condition. But typically, only hospitalized COVID-19 patients in need of oxygen are given the drug.
